Monocyte procoagulant activity in Whipple's disease. 1984

C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy

We have studied the expression of procoagulant activity by the circulating mononuclear cells of four patients with Whipple's disease. There was a spontaneous expression of procoagulant activity in two patients with active untreated Whipple's disease. This activity was shown to originate in the monocyte fraction of the mononuclear cells and was demonstrated to cleave prothrombin directly. This prothrombinase activity was not Factor Xa, because it was not neutralized by anti-Factor X serum and was not inhibited by an established panel of Factor Xa inhibitors. The prothrombinase activity was not expressed by the monocytes of these patients following 8 weeks of antibiotic therapy, by which time the patients' symptoms resolved, and was not found in two patients previously treated for Whipple's disease who were in clinical remission or in normal subjects. Serial studies in one patient with active disease showed that monocytes failed to express increased prothrombinase within 2 weeks of antibiotic therapy. A second procoagulant activity was produced in response to endotoxin (LPS) by cells from controls and patients with Whipple's disease and was identified as thromboplastin. These observations suggest that circulating monocytes of patients with active Whipple's disease are endogenously stimulated to express prothrombinase activity, which may contribute, at least in part, to the pathophysiology of this condition.

UI MeSH Term Description Entries
D008061 Whipple Disease A chronic systemic infection by a gram-positive bacterium, Tropheryma whippelii, mainly affecting the SMALL INTESTINE but also the JOINTS; CARDIOVASCULAR SYSTEM; and the CENTRAL NERVOUS SYSTEM. The disease is characterized by fat deposits in the INTESTINAL MUCOSA and LYMPH NODES, malabsorption, DIARRHEA with fatty stools, MALNUTRITION, and ARTHRITIS. Lipodystrophy, Intestinal,Whipple's Disease,Disease, Whipple,Disease, Whipple's,Intestinal Lipodystrophy,Whipples Disease
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D005165 Factor V Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease. Coagulation Factor V,Proaccelerin,AC Globulin,Blood Coagulation Factor V,Factor 5,Factor Five,Factor Pi,Factor V, Coagulation
D005170 Factor X Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder. Autoprothrombin III,Coagulation Factor X,Stuart Factor,Stuart-Prower Factor,Blood Coagulation Factor X,Factor 10,Factor Ten,Stuart Prower Factor,Factor X, Coagulation
D005260 Female Females

Related Publications

C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
July 1987, Thrombosis research,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
August 1983, Lancet (London, England),
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
January 1986, Thrombosis research,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
August 1990, Transplantation,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
October 1991, Seminars in thrombosis and hemostasis,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
December 1990, Lancet (London, England),
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
January 1993, Autoimmunity,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
November 1990, Journal of clinical & laboratory immunology,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
September 2001, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
C A Ottaway, and R E Warren, and F G Saibil, and L S Fung, and D S Fair, and G A Levy
January 1995, Seminars in thrombosis and hemostasis,
Copied contents to your clipboard!